U.S. Markets open in 27 mins

StemCells receives FDA authorization of IND for spinal cord injury

StemCells announced that the FDA has authorized the company's Investigational New Drug, or IND, application for clinical testing of the company's proprietary HuCNS-SC human neural stem cells as a treatment for spinal cord injury. As a first action under this IND, the company is working to open U.S. sites for its Phase I/II clinical trial for chronic spinal cord injury, which is currently underway in Switzerland and Canada.